Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -695.56% is 563% below its 5-year average of -104.93%, near the low end of its 5-year range (-867.84%–-9.45%).
As of the fiscal period ended Tuesday, June 30, 2026. 5.59% below its 12-month average of -658.74%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -695.56%.
RETURN ON EQUITY (ROE)
-695.56%
RETURN ON EQUITY (ROE) AVG TTM
-658.74%
RETURN ON EQUITY (ROE) AVG 3Y
-348.12%
RETURN ON EQUITY (ROE) AVG 5Y
-104.93%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-5.59%
CURRENT VS 3Y AVG
-99.81%
CURRENT VS 5Y AVG
-562.88%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.89%
median of 686 covered companies
CURRENT VS SECTOR MEDIAN
-1601.06%
vs the sector median at left
Greenwich LifeSciences, Inc.
Market Cap
$242.78M
Return on Equity (ROE)
-695.56%
TTM Avg
-658.74%
3Y Avg
-348.12%
5Y Avg
-104.93%
Market Cap
$242.31M
Return on Equity (ROE)
N/A
TTM Avg
-1340.59%
3Y Avg
-55.32%
5Y Avg
-61.68%
Market Cap
$242.02M
Return on Equity (ROE)
N/A
TTM Avg
35.05%
3Y Avg
64.68%
5Y Avg
-167.54%
Market Cap
$241.78M
Return on Equity (ROE)
-43.11%
TTM Avg
-35.75%
3Y Avg
-28.47%
5Y Avg
-12.53%
Market Cap
$244.06M
Return on Equity (ROE)
31.90%
TTM Avg
-385.06%
3Y Avg
-191.20%
5Y Avg
-142.10%
Market Cap
$240.52M
Return on Equity (ROE)
-59.27%
TTM Avg
-136.66%
3Y Avg
-113.26%
5Y Avg
-53.68%
Market Cap
$240.34M
Return on Equity (ROE)
N/A
TTM Avg
-125.28%
3Y Avg
-42.20%
5Y Avg
-43.41%
Market Cap
$246.31M
Return on Equity (ROE)
-54.67%
TTM Avg
-46.45%
3Y Avg
-41.29%
5Y Avg
-47.75%
Market Cap
$238.61M
Return on Equity (ROE)
-27.27%
TTM Avg
-92.43%
3Y Avg
-64.95%
5Y Avg
-57.80%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | $242.78M | -695.56% | -658.74% | -348.12% | -104.93% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $242.31M | N/A | -1340.59% | -55.32% | -61.68% |
| Galectin Therapeutics Inc. (GALT)vs › | $242.02M | N/A | 35.05% | 64.68% | -167.54% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $241.78M | -43.11% | -35.75% | -28.47% | -12.53% |
| Q32 Bio Inc. (QTTB)vs › | $244.06M | 31.90% | -385.06% | -191.20% | -142.10% |
| Invivyd, Inc. (IVVD)vs › | $240.52M | -59.27% | -136.66% | -113.26% | -53.68% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $240.34M | N/A | -125.28% | -42.20% | -43.41% |
| Quantum-Si incorporated (QSI)vs › | $246.31M | -54.67% | -46.45% | -41.29% | -47.75% |
| InflaRx N.V. (IFRX)vs › | $238.61M | -27.27% | -92.43% | -64.95% | -57.80% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $237.27M | -118.58% | 62.37% | -376.78% | -340.60% |
ROE
-695.6%
ROA
-244.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -695.56% |
| 2026-03-31 | -412.83% |
| 2025-09-30 | -867.84% |
| 2024-12-31 | -623.07% |
| 2024-09-30 | -210.64% |
| 2024-06-30 | -173.92% |
| 2024-03-31 | -180.44% |
| 2023-12-31 | -132.71% |
| 2023-09-30 | -100.94% |
| 2023-06-30 | -83.22% |
| 2023-03-31 | -68.30% |
| 2022-12-31 | -59.22% |
| 2022-09-30 | -47.99% |
| 2022-06-30 | -35.00% |
| 2022-03-31 | -30.46% |
| 2021-12-31 | -17.03% |
| 2021-09-30 | -11.81% |
| 2021-06-30 | -9.45% |
| 2021-03-31 | -7.45% |
| 2020-12-31 | -6.74% |
| 2020-09-30 | -22.51% |
